^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thymidine phosphorylase inhibitor

    Related drugs:
    5d
    BEST: SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=58, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    6d
    Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer. (PubMed, Oncologist)
    Our predictive model may help identify patients at high risk of early mortality after regorafenib or trifluridine/tipiracil initiation and support shared decision-making between clinicians and patients regarding further chemotherapy or best supportive care.
    Journal
    |
    CRP (C-reactive protein)
    |
    Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    9d
    Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas (clinicaltrials.gov)
    P1, N=22, Recruiting, University of California, Irvine | Trial completion date: Dec 2026 --> Jan 2028 | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    capecitabine • irinotecan • Lonsurf (trifluridine/tipiracil)
    13d
    Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . (clinicaltrials.gov)
    P1/2, N=45, Recruiting, National Health Research Institutes, Taiwan | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • Onivyde (nanoliposomal irinotecan)
    14d
    TriComB: Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (clinicaltrials.gov)
    P1/2, N=48, Active, not recruiting, Gruppo Oncologico Del Nord Ovest | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Avastin (bevacizumab) • capecitabine • Lonsurf (trifluridine/tipiracil)
    20d
    Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, University of Wisconsin, Madison | Active, not recruiting --> Recruiting | N=25 --> 50 | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive • HER-2 positive + RAS wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Onivyde (nanoliposomal irinotecan)
    26d
    Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study. (PubMed, ESMO Open)
    In this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRASG12 mutations.
    Clinical data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12
    |
    Avastin (bevacizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    28d
    Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans (clinicaltrials.gov)
    P=N/A, N=76, Completed, Shandong New Time Pharmaceutical Co., LTD
    New trial
    |
    Lonsurf (trifluridine/tipiracil)
    29d
    Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study (clinicaltrials.gov)
    P1/2, N=106, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P1/2 trial • Checkpoint inhibition
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    1m
    BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study. (2024-520128-27-00)
    P1/2, N=162, Recruiting, Association Gercor | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • BRAF wild-type • RAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    1m
    Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=52, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Lonsurf (trifluridine/tipiracil)
    2ms
    BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study. (2024-520128-27-00)
    P1/2, N=162, Not yet recruiting, Association Gercor
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • BRAF wild-type • RAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)